IN THE MARATHON OF MYELOMA TREATMENT,
ARE YOU DROPPING THE PROTEASOME INHIBITOR TOO SOON?
Continuous treatment with a proteasome inhibitor (PI)–based regimen is associated with clinical benefits, including for patients with high-risk cytogenetics.1-3 However, many patients who have had 1 prior therapy receive injectable PIs for only 4 to 7 months.4,5
The NINLARO® (ixazomib) regimen extended median PFS by ~6 months (median: 20.6 vs 14.7 months) vs placebo regimen in patients with multiple myeloma who have received at least 1 prior therapy.1*†
NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.SEE THE PATH TO EXTENDED PFS